Baseline characteristics
MENSA BASELINE CHARACTERISTICS1,2
| NUCALA (n=194) | Placebo (n=191) | |
| Mean age | 51 years | 49 years |
| Female | 60% | 56% |
| Body mass index* | 27.6 | 28.0 |
| Duration of asthma | 20.5 years | 19.5 years |
| Use of oral glucocorticoids | ||
| Maintenance use | 27% | 23% |
| Mean daily dose† | 12.6 mg | 15.1 mg |
| Allergic rhinitis | 49% | 50% |
| Nasal polyposis | 14% | 17% |
| FEV1 | ||
| Before bronchodilation‡ | 1.73 L | 1.86 L |
| Predicted value before bronchodilation§ | 59.3% | 62.4% |
| Reversibility | 27.9% | 27.4% |
| FEV1/FVC ratio | 63% | 64% |
| ACQ-5 score|| | 2.26 | 2.28 |
| SGRQ score¶ | 47.9 | 46.9 |
| Geometric mean IgE on loge scale | 150 U/mL | 150 U/mL |
| Geometric mean blood eosinophil count on loge scale | 290 cells/μL | 320 cells/μL |
| Asthma exacerbations | ||
| Severe episodes in previous year | 3.8 | 3.6 |
| Necessitating hospitalization in the previous year | 17% | 18% |
- *Body mass index is the weight in kilograms divided by the square of the height in meters.
- †The listed value is the prednisone equivalent.
- ‡Reversibility was measured at baseline.
- §The percent of predicted value before bronchodilation was assessed at the screening visit.
- llScores on the ACQ range from 0 to 6 with higher scores indicating worse control; a change of 0.5 points is the minimal clinically important difference.3
- ¶Scores on the SGRQ range from 0 to 100 with higher scores indicating worse function; a change of 4 points is considered to be clinically relevant.4,5
- ACQ=Asthma Control Questionnaire; FEV1=forced expiratory volume in 1 second; FVC=forced vital capacity;
- IgE=immunoglobulin E; IV=intravenous; SGRQ=St. George’s Respiratory Questionnaire.